MedTrace Logo

PLasmatic Extracellular Vesicles AS Biomarkers of nEural Tissue Damage

NCT07769294 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-08-17

No results posted yet for this study

Summary

Recently proposed central nervous system damage biomarkers detectable in biofluids, such as neurofilament light chain (NfL) have several limits, including a lack in specificity and a kinetic that does not allow them to be used as outcome measures in clinical trials for neurodegenerative diseases such as the progressive forms of multiple sclerosis (MS) or the sequelae of stroke. Our team has pioneered the detection of central nervous system (CNS) extracellular vesicles (EVs) as biomarkers in MS and Alzheimer's Disease. If EVs are not the best solution themselves, we propose also to investigate their content to reveal potential new biomarkers having the same significance and an easier detection technology. Thus, we propose here to set-up front line technologies to detect EVs of CNS origin, or their content, in the plasma of persons affected by MS or by stroke to find better ways to monitor ongoing neurodegenerative processes and therefore allow easier development of new treatments.

Conditions

Sponsors & Collaborators

  • IRCCS Santa Lucia Foundation, Rome

    collaborator UNKNOWN

  • Roberto Furlan

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-15
Primary Completion
2028-03-31
Completion
2028-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07769294 on ClinicalTrials.gov